ACHILLION PHARMACEUTICALS INC
ACHILLION PHARMACEUTICALS INC (ACHN): 4 pipeline candidates · ~27 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
27.2 months
D/E 0.09 · 0% dilution
Lead: Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for ACHILLION PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$43.7M
Quarterly Burn
$16.5M
Runway
27.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| ach-4471 | Phase 2 |
| ach-5228 | Phase 1 |
| ach-5548 | Preclinical |
| oral factor d inhibitors | Preclinical |
Frequently asked questions
How many drug candidates are in ACHILLION PHARMACEUTICALS INC's pipeline?
ACHILLION PHARMACEUTICALS INC (ACHN) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ACHILLION PHARMACEUTICALS INC's lead drug candidate?
ACHILLION PHARMACEUTICALS INC's most advanced tracked candidate is ach-4471 (Phase 2) for C3 glomerulopathy (C3G), immune complex membranoproliferative glomerulonephritis (IC-MPGN), and paroxysmal nocturnal hemoglobinuria (PNH).
What is ACHILLION PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ACHILLION PHARMACEUTICALS INC has approximately 27.2 months of cash runway.
Who is the CEO of ACHILLION PHARMACEUTICALS INC?
Intarcia Therapeutics is the chief executive officer of ACHILLION PHARMACEUTICALS INC (ACHN).
Get the full picture on ACHILLION PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.